Travere

Biopharmaceutical company developing therapies for people with rare kidney and metabolic diseases

+ Add to sales board

Highlights

  • New on EvolcAdded 2026-11-14

Recent signals

What changed at Travere in the last 6 months, newest first. Each line links to its public source.

Get signals like these for the companies you sell to →

About Travere

Travere Therapeutics is a biopharmaceutical company that works to identify, develop and deliver therapies for people living with rare kidney and metabolic diseases. Its pipeline includes pegtibatinase for classical homocystinuria (HCU) and civorebrutinib, a BTK inhibitor, for multiple immune-mediated rare kidney diseases. Listed therapeutic areas are HCU, cystinuria, focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).

Its customers are patients with rare kidney and metabolic diseases, their families and caregivers, and the clinicians who treat them. Its commercial organisation includes medical science liaisons, strategic account managers, specialty pharmacy and distribution functions, and marketing for FILSPARI (sparsentan). The company also supports newborn screening programmes and telehealth access to rare disease care.

The company reports 500 people. Its CEO is Eric Dube, Ph.D. Travere publishes quarterly financial results and takes part in investor conferences. Current open roles span medical science liaison and field medical positions, clinical development, regulatory, CMC, quality, pharmacovigilance and corporate functions, many of them remote-eligible across US states.

Product: Pharmaceutical therapies for rare kidney and metabolic diseases, including the pipeline candidates pegtibatinase and civorebrutinib and the marketed FILSPARI (sparsentan).

Jobs at Travere

No open positions listed right now.

More biotech & pharma companies

  • Treeline Biosciences

    Develops targeted medicines for patients with cancer and other serious diseases
    United StatesBiotech & pharma
    New on Evolc
  • Twist Bioscience

    Synthetic DNA, oligo pools and NGS target enrichment products for life science researchers and biotech teams
    United StatesBiotech & pharma
    New on Evolc
  • TwoStep Therapeutics

    Developing peptide-based targeted cancer therapies for patients with solid tumors
    United StatesBiotech & pharma
    New on Evolc
  • Ultima Genomics

    DNA sequencing platforms (UG200 series) for labs, genomics service providers and research institutions
    United StatesBiotech & pharma
    New on Evolc
  • Universal DX

    Develops blood-based early cancer detection tests for clinical and healthcare partners
    United StatesBiotech & pharma
    New on Evolc
  • Valo Health

    AI-enabled drug discovery and development for pharmaceutical and biotech partners
    United StatesBiotech & pharma
    New on Evolc

All biotech & pharma companies →

Website technologies

Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.

Analytics

  • Google Tag ManagerMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Content delivery

Content management

  • WordPressHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Forms

  • Google reCAPTCHAHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Frontend frameworks

  • jQueryHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence
  • Tailwind CSSMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Marketing & advertising

  • LinkedIn InsightMedium confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Privacy & consent

  • OneTrustHigh confidence
    First detected
    Last detected
    Last checked
    Detection evidence

Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.